HLB Pharmaceutical Co. Ltd (047920) — Cash Flow Reinvestment Rate
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Reinvestment Rate of 2.46x as of September 2025, reinvesting ₩4.60 Billion (capex ₩2.26 Billion plus investments ₩2.34 Billion) from operating cash flow of ₩1.86 Billion. Check 047920 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
HLB Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for HLB Pharmaceutical Co. Ltd across 3 annual periods. Explore how much of HLB Pharmaceutical Co. Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for HLB Pharmaceutical Co. Ltd. For live market cap and broader valuation context, see 047920 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.24x | ₩15.35 Billion | ₩6.84 Billion | ₩3.09 Billion | ▼ -53.0% |
| 2019 | 4.77x | ₩6.46 Billion | ₩1.35 Billion | ₩1.40 Billion | ▲ +95.2% |
| 2014 | 2.44x | ₩3.77 Billion | ₩1.54 Billion | ₩2.26 Billion | — |